Recently, at a critical juncture of profound change in the pharmaceutical industry, the Conference on Industrial Innovation, Transformation, and Investment Matchmaking was grandly convened. Currently, the dual pressures of the normalization of volume-based procurement and the peaking of dividends from generic drugs are forcing pharmaceutical enterprises to stand at a crossroads of transformation. Should they focus on innovation or layout for global expansion? Should they deepen their roots in traditional dosage forms or break through into high-end preparations? These topics became the focus of heated discussion at the conference. KornnacCaps was invited to attend and, as the only company exhibiting empty capsule at the event, provided a solid answer to the industry's transformation anxiety with its forward-looking quality philosophy and leading processes.
Across two conferences and dozens of professional reports, ranging from new drug R&D to high-end complex preparations, and from TCM innovation to transdermal drug delivery, the events revealed the industry's urgent desire for differentiated innovation, as well as the huge opportunities driven by the multi-engine combination of Innovation + Global Expansion + Consumption. However, opportunities often coexist with challenges. On the path toward high-end preparations and international projects, the safety, stability, and compliance of pharmaceutical excipients have become key shortcomings that restrict the success of R&D.
At the exhibition, KornnacCaps prominently showcased products featuring its unique leading EtO-Free Sterilization process. Distinct from traditional industry practices, KornnacCaps achieves high-standard cleanliness requirements without the need for Ethylene Oxide sterilization through rigorous microbial control across the entire Man, Machine, Material, Method, and Environment process. This technological breakthrough signifies safer excipient attributes, a more stable supply guarantee, and reduced compliance risks, perfectly aligning with the stringent demands for high-safety excipients in current innovative drug and international projects.
As the sole enterprise exhibiting empty capsule, KornnacCaps brought not only high-quality products but also a core philosophy of safeguarding quality from the source. Facing the diverse needs of innovative drug preparations, high-end complex formulations, and international projects, KornnacCaps demonstrated strong empowerment capabilities. Dedicated to becoming a reliable partner on the path of pharmaceutical enterprise transformation, the company provides reliable empty capsule solutions, helping products reach the market faster and more stably.
This exhibition not only showcased KornnacCaps's technical leadership in the field of empty capsules but also reflected its sense of responsibility to share weal and woe with the industry. Amid the tide of innovation and transformation in the pharmaceutical industry, KornnacCaps will continue to use source quality as its cornerstone, helping partners break through obstacles and embark on a new journey of high-quality development together.
